Diversified Management Inc. Invests $909,000 in Merck & Co., Inc. $MRK

Key Points

• Diversified Management Inc. bought a new position of 8,638 Merck shares in Q4 valued at approximately $909,000, while institutional ownership of MRK stands around 76.07% and several other funds also increased stakes.
• Multiple analysts have upgraded Merck recently—Wolfe, Deutsche Bank and others raised ratings/targets—and the consensus is a "Moderate Buy" with an average price target of $128.47.
• Merck posted a Q4 earnings beat (EPS $2.04 vs. $2.01) with revenue of $16.4B (+5% YoY), set FY2026 EPS guidance of 5.000–5.150, and pays a quarterly dividend of $0.85 (about a 2.9% yield).

Diversified Management Inc. bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,638 shares of the company's stock, valued at approximately $909,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Childress Capital Advisors LLC increased its holdings in Merck & Co., Inc. by 71.7% in the fourth quarter. Childress Capital Advisors LLC now owns 22,819 shares of the company's stock worth $2,402,000 after purchasing an additional 9,529 shares in the last quarter. KBC Group NV boosted its holdings in shares of Merck & Co., Inc. by 9.2% during the 4th quarter. KBC Group NV now owns 1,278,131 shares of the company's stock worth $134,535,000 after buying an additional 107,602 shares in the last quarter. Towne Trust Company N.A grew its position in shares of Merck & Co., Inc. by 6.9% during the 4th quarter. Towne Trust Company N.A now owns 24,161 shares of the company's stock worth $2,543,000 after buying an additional 1,552 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its position in shares of Merck & Co., Inc. by 14.9% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 17,000 shares of the company's stock worth $1,789,000 after buying an additional 2,200 shares during the period. Finally, Adelphi Trust Co bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $1,155,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Analyst Ratings Changes

MRK has been the topic of a number of research reports. Wolfe Research upgraded shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price on the stock in a research report on Thursday, January 8th. Citigroup lifted their price target on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the company a "neutral" rating in a research note on Friday, March 20th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price objective on the stock in a report on Friday, February 13th. Cantor Fitzgerald increased their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and an average price target of $128.47.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $118.07 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock's fifty day simple moving average is $119.26 and its two-hundred day simple moving average is $105.51. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock has a market cap of $291.62 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio is presently 46.70%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. NYSE: MRK Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA XTRA: MRK appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA XTRA: MRK Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here's Why

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares in the company, valued at approximately $2,583,278.39. This trade represents a 41.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 320,176 shares of company stock worth $38,281,735 in the last ninety days. 0.13% of the stock is owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.